Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listLacosamide

Lacosamide

  • CAS NO.:175481-36-4
  • Empirical Formula: C13H18N2O3
  • Molecular Weight: 250.29
  • MDL number: MFCD08272557
  • EINECS: 605-756-0
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-10-23 13:36:13
Lacosamide Structural

What is Lacosamide?

Absorption

Lacosamide has a negligible first pass effect with bioavailability of about 100%. The maximum Lacosamide plasma concentrations occur about 1-4 hours after oral administration, and the pharmacokinetics of Lacosamide are dose proportional. Food does not affect absorption.

Description

Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.

Description

Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.

Chemical properties

White to Off-White Solid

Originator

Harris FRC (United States)

The Uses of Lacosamide

A potent anticonvulsant.

Indications

Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.

Background

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.

Definition

ChEBI: Lacosamide is a N-acyl-amino acid.

brand name

Vimpat

Pharmacokinetics

Lacosamide therapy is correlated with a decrease in seizure frequency. It should be noted that in group analyses, dosages above 400 mg/day do not appear to result in additional benefit.

Synthesis

The most common adverse events were diplopia, headache, dizziness, and nausea. As typical with AEDs, lacosamide may increase the risk of suicidal thoughts or behavior. Patients should, therefore, be monitored for the emergence or worsening of depression. Caution should also be exercised in patients with known conduction problems or severe cardiac disease (myocardial ischemia or heart failure) since dose-dependent prolongations in PR interval have been observed in clinical studies.

Metabolism

Lacosamide is a CYP2C19 substrate. The relative contribution of other CYP isoforms or non-CYP enzymes in the metabolism of lacosamide is not known. Primary compounds excreted were unchanged lacosamide (approximately 40% of the dose), its O-desmethyl metabolite (approximately 30%), and a structurally unknown polar fraction (~20%). The plasma exposure of the major human metabolite, O-desmethyl-lacosamide, is approximately 10% of that of lacosamide. This metabolite has no known pharmacological activity.

Properties of Lacosamide

Melting point: 141-143?C
Boiling point: 536.4±50.0 °C(Predicted)
alpha  D23 +16.0° (c = 1 in CH3OH)
Density  1.120±0.06 g/cm3(Predicted)
Flash point: 2℃
storage temp.  Refrigerator
solubility  DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
form  A crystalline solid
pka 14.19±0.46(Predicted)
InChI InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
CAS DataBase Reference 175481-36-4

Safety information for Lacosamide

Signal word Danger
Pictogram(s)
ghs
Flame
Flammables
GHS02
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H225:Flammable liquids
H319:Serious eye damage/eye irritation
Precautionary Statement Codes P210:Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Lacosamide

InChIKey VPPJLAIAVCUEMN-GFCCVEGCSA-N
SMILES C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC

Abamectin manufacturer

KARPSCHEM LABORATORIES PVT. LTD.

1Y
Phone:+917249203006
Whatsapp: +91 7249203006
product: Lacosamide (2R)-2-(Acetylamino)-3-methoxy-N- (phenylmethyl)propanamide 96%
Inquiry

Varanous Labs Pvt Ltd

1Y
Phone:+917036248882
Whatsapp: +91 7036248882
product: S-Lacosamide 175481-36-4 98%
Inquiry

Metrochem API Private Limited

1Y
Phone:+91-4069069999
product: Lacosamide 98%
Inquiry

Aalidhra Pharmachem Pvt Ltd

1Y
Phone:+91-9879180894
Whatsapp: +91 9879180894
product: 175481-36-4 98%
Inquiry

Lupin Ltd

1Y
Phone:+91-8019896181
Whatsapp: +91 8019896181
product: Lacosamide 175481-36-4 99%
Inquiry

Apotex Pharmachem India Pvt Ltd

1Y
Phone:+91-8022891000
product: Lacosamide 98%
Inquiry

Alembic Pharmaceuticals Limited

1Y
Phone:+912652280550
product: 175481-36-4 Lacosamide 98%
Inquiry

Glenmark Pharmaceuticals Limited

1Y
Phone:+912240189999
product: 175481-36-4 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: Lacosamide 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.